Ümit Özgür AKDEMİR, Lütfiye Özlem ATAY, Ayşe BORA TOKÇAER

Dopamine transporter SPECT imaging in Parkinson’s disease and parkinsonian disorders

Abstract: The dopamine transporter (DAT) imaging provides an objective tool for the assessment of dopaminergic function of presynaptic terminals which is valuable for the differential diagnosis of parkinsonian disorders related to a striatal dopaminergic deficiency from movement disorders not related a striatal dopaminergic deficiency. DAT imaging with single-photon emission computed tomography (SPECT) can be used to confirm or exclude a diagnosis of dopamine deficient parkinsonism in cases where the diagnosis is unclear. It can also detect the dopaminergic dysfunction in presymptomatic subjects at risk for Parkinson’s disease (PD) since the reduced radiotracer binding to DATs in striatum is already present in the prodromal stage of PD. This review covers the rationale of using DAT SPECT imaging in the diagnosis of PD and other parkinsonian disorders, specifically focusing on the practical aspects of imaging and routine clinical indications.Key words: Dopamine transporter, 123I-ioflupane, SPECT, Parkinson’s disease, parkinsonian disorders

PDF

___

1. Palermo G, Ceravolo R. Molecular imaging of the dopamine transporter. Cells 2019; 8 (8): 872. doi: 10.3390/cells8080872
2. Miller DB, O’Callaghan JP. Biomarkers of Parkinson’s disease: present and future. Metabolism-Clinical and Experimental 2015; 64 (3): S40-S46. doi: 10.1016/j.metabol.2014.10.030
3. Fazio P, Svenningsson P, Cselenyi Z, Halldin C, Farde L et al. Nigrostriatal dopamine transporter availability in early Parkinson’s disease. Movement Disorders 2018; 33 (4): 592-599. doi: 10.1002/mds.27316
4. Brooks DJ. Molecular imaging of dopamine transporters. Ageing Research Reviews 2016; 30: 114-121. doi: 10.1016/j. arr.2015.12.009
5. Darcourt J, Booij J, Tatsch K, Varrone A, Vander Borght T et al. EANM procedure guidelines for brain neurotransmission SPECT using (123)I-labelled dopamine transporter ligands, version 2. European Journal of Nuclear Medicine and Molecular Imaging 2010; 37 (2): 443-450. doi: 10.1007/s00259-009- 1267-x
6. Morbelli S, Esposito G, Arbizu J, Barthel H, Boellaard R et al. EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0. European Journal of Nuclear Medicine and Molecular Imaging 2020; 47 (8): 1885-1912. doi: 10.1007/s00259-020-04817-8
7. Akdemir ÜÖ, Atay LÖ, Aydın F, Çakır T, Kaya M et al. Parkinsonyen sendromlarda dopaminerjik görüntüleme kılavuzu. Nuclear Medicine Seminars 2020; 2 (6): 243-255 (in Turkish). doi: 10.4274/nts.galenos.2020.0019
8. Subramaniam RM, Frey KA, Hunt CH, Mercier GA Jr., Solnes LB et al. ACR-ACNM practice parameter for the performance of dopamine transporter (DaT) single photon emission computed tomography (SPECT) imaging for movement disorders. Clinical Nuclear Medicine 2017; 42 (11): 847-852. doi: 10.1097/ RLU.0000000000001815
9. Djang DS, Janssen MJ, Bohnen N, Booij J, Henderson TA et al. SNM practice guideline for dopamine transporter imaging with 123I-ioflupane SPECT 1.0. Journal of Nuclear Medicine 2012; 53 (1): 154-163. doi: 10.2967/jnumed.111.100784
10. Van Laere K, Varrone A, Booij J, Vander Borght T, Nobili F et al. EANM procedure guidelines for brain neurotransmission SPECT/PET using dopamine D2 receptor ligands, version 2. European Journal of Nuclear Medicine and Molecular Imaging 2010; 37 (2): 434-442. doi: 10.1007/s00259-009-1265-z
11. Hellwig S, Amtage F, Kreft A, Buchert R, Winz OH et al. [(1) (8)F]FDG-PET is superior to [(1)(2)(3)I]IBZM-SPECT for the differential diagnosis of parkinsonism. Neurology 2012; 79 (13): 1314-1322. doi: 10.1212/WNL.0b013e31826c1b0a
12. Treglia G, Cason E, Stefanelli A, Cocciolillo F, Di Giuda D et al. MIBG scintigraphy in differential diagnosis of Parkinsonism: a meta-analysis. Clinical Autonomic Research 2012; 22 (1): 43- 55. doi: 10.1007/s10286-011-0135-5
13. Dickson JC, Tossici-Bolt L, Sera T, De Nijs R, Booij J et al. Proposal for the standardisation of multi-centre trials in nuclear medicine imaging: prerequisites for a European 123I-FP-CIT SPECT database. European Journal of Nuclear Medicine and Molecular Imaging 2012; 39 (1): 188-197. doi: 10.1007/s00259- 011-1884-z
14. Dickson JC, Tossici-Bolt L, Sera T, Erlandsson K, Varrone A et al. The impact of reconstruction method on the quantification of DaTSCAN images. European Journal of Nuclear Medicine and Molecular Imaging 2010; 37 (1): 23-35. doi: 10.1007/ s00259-009-1212-z
15. Tossici-Bolt L, Dickson JC, Sera T, Booij J, Asenbaun-Nan S et al. [(123)I]FP-CIT ENC-DAT normal database: the impact of the reconstruction and quantification methods. EJNMMI Physics 2017; 4 (1): 8. doi: 10.1186/s40658-017-0175-6
16. Tossici-Bolt L, Dickson JC, Sera T, De Nijs R, Bagnara MC et al. Calibration of gamma camera systems for a multicentre European (1)(2)(3)I-FP-CIT SPECT normal database. European Journal of Nuclear Medicine and Molecular Imaging 2011; 38 (8): 1529-1540. doi: 10.1007/s00259-011-1801-5
17. Varrone A, Dickson JC, Tossici-Bolt L, Sera T, Asenbaum S et al. European multicentre database of healthy controls for [123I]FP-CIT SPECT (ENC-DAT): age-related effects, gender differences and evaluation of different methods of analysis. European Journal of Nuclear Medicine and Molecular Imaging 2013; 40 (2): 213-227. doi: 10.1007/s00259-012-2276-8
18. Berg D, Postuma RB, Adler CH, Bloem BR, Chan P et al. MDS research criteria for prodromal Parkinson’s disease. Movement Disorders 2015; 30 (12): 1600-1609. doi: 10.1002/mds.26431
19. Filippi M, Agosta F, Barkhof F, Dubois B, Fox NC et al. EFNS task force: the use of neuroimaging in the diagnosis of dementia. European Journal of Neurology 2012; 19 (12): 1487-1501. doi: 10.1111/j.1468-1331.2012.03859.x
20. McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP et al. Diagnosis and management of dementia with Lewy bodies Fourth consensus report of the DLB Consortium. Neurology 2017; 89 (1): 88-100. doi: 10.1212/Wnl.0000000000004058
21. Marek K, Jennings D, Lasch S, Siderowf A, Tanner C et al. The Parkinson Progression Marker Initiative (PPMI). Progress in Neurobiology 2011; 95 (4): 629-635. doi: 10.1016/j.pneurobio.2011.09.005
22. Simuni T, Siderowf A, Lasch S, Coffey CS, Caspell-Garcia C et al. Longitudinal change of clinical and biological measures in early Parkinson’s disease: Parkinson’s progression markers initiative cohort. Movement Disorders 2018; 33 (5): 771-782. doi: 10.1002/mds.27361
23. Booij J, Kemp P. Dopamine transporter imaging with [(123)I] FP-CIT SPECT: potential effects of drugs. European Journal of Nuclear Medicine and Molecular Imaging 2008; 35 (2): 424- 438. doi: 10.1007/s00259-007-0621-0
24. Proebstl L, Kamp F, Manz K, Krause D, Adorjan K et al. Effects of stimulant drug use on the dopaminergic system: a systematic review and meta-analysis of in vivo neuroimaging studies. European Psychiatry 2019; 59: 15-24. doi: 10.1016/j. eurpsy.2019.03.003
25. Kamp F, Proebstl L, Penzel N, Adorjan K, Ilankovic A et al. Effects of sedative drug use on the dopamine system: a systematic review and meta-analysis of in vivo neuroimaging studies. Neuropsychopharmacology 2019; 44 (4): 660-667. doi: 10.1038/s41386-018-0191-9
26. Booij J, De Jong J, De Bruin K, Knol R, De Win MM et al. Quantification of striatal dopamine transporters with 123IFP-CIT SPECT is influenced by the selective serotonin reuptake inhibitor paroxetine: a double-blind, placebo-controlled, crossover study in healthy control subjects. Journal of Nuclear Medicine 2007; 48 (3): 359-366.
27. Cilia R, Marotta G, Belletti A, Siri C, Pezzoli G. Reversible dopamine transporter reduction in drug-induced Parkinsonism. Movement Disorders 2014; 29 (4): 575-577. doi: 10.1002/ mds.25828
28. Jones JG, Mills CN, Mogensen MA, Lee CI. Radiation dose from medical imaging: a primer for emergency physicians. Western Journal of Emergency Medicine 2012; 13 (2): 202-210. doi: 10.5811/westjem.2011.11.6804
29. Grosset DG, Tatsch K, Oertel WH, Tolosa E, Bajaj N et al. Safety analysis of 10 clinical trials and for 13 years after first approval of ioflupane I-123 injection (DaTscan). Journal of Nuclear Medicine 2014; 55 (8): 1281-1287. doi: 10.2967/ jnumed.114.138032
30. Booij J, Dubroff J, Pryma D, Yu J, Agarwal R et al. Diagnostic performance of the visual reading of (123)I-ioflupane SPECT images with or without quantification in patients with movement disorders or dementia. Journal of Nuclear Medicine 2017; 58 (11): 1821-1826. doi: 10.2967/jnumed.116.189266
31. Seibyl JP, Marek K, Sheff K, Zoghbi S, Baldwin RM et al. Iodine123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson’s patients. Journal of Nuclear Medicine 1998; 39 (9): 1500-1508.
32. Albert NL, Unterrainer M, Diemling M, Xiong GM, Bartenstein P et al. Implementation of the European multicentre database of healthy controls for [I-123]FP-CIT SPECT increases diagnostic accuracy in patients with clinically uncertain parkinsonian syndromes. European Journal of Nuclear Medicine and Molecular Imaging 2016; 43 (7): 1315-1322. doi: 10.1007/ s00259-015-3304-2
33. Marshall VL, Reininger CB, Marquardt M, Patterson J, Hadley DM et al. Parkinson’s disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: a 3-year European multicenter study with repeat [123I]FP-CIT SPECT. Movement Disorders 2009; 24 (4): 500-508. doi: 10.1002/mds.22108
34. Nicastro N, Garibotto V, Burkhard PR. 123I-FP-CIT SPECT Accurately distinguishes Parkinsonian from cerebellar variant of multiple system atrophy. Clinical Nuclear Medicine 2018; 43 (2): e33-e36. doi: 10.1097/RLU.0000000000001899
35. Bauckneht M, Chincarini A, De Carli F, Terzaghi M, Morbelli S et al. Presynaptic dopaminergic neuroimaging in REM sleep behavior disorder: a systematic review and meta-analysis. Sleep Medicine Reviews 2018; 41: 266-274. doi: 10.1016/j. smrv.2018.04.001
36. Kordower JH, Olanow CW, Dodiya HB, Chu Y, Beach TG et al. Disease duration and the integrity of the nigrostriatal system in Parkinson’s disease. Brain 2013;136 (Pt 8): 2419-2431. doi: 10.1093/brain/awt192
37. Marek K, Seibyl J, Eberly S, Oakes D, Shoulson I et al. Longitudinal follow-up of SWEDD subjects in the PRECEPT Study. Neurology 2014; 82 (20): 1791-1797. doi: 10.1212/ WNL.0000000000000424
38. Erro R, Schneider SA, Stamelou M, Quinn NP, Bhatia KP. What do patients with scans without evidence of dopaminergic deficit (SWEDD) have? New evidence and continuing controversies. Journal of Neurology Neurosurgery and Psychiatry 2016; 87 (3): 319-323. doi: 10.1136/jnnp-2014-310256
39. Lee CS, Samii A, Sossi V, Ruth TJ, Schulzer M et al. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson’s disease. Annals of Neurology 2000; 47 (4): 493-503.
40. Kaasinen V, Vahlberg T. Striatal dopamine in Parkinson disease: a meta-analysis of imaging studies. Annals of Neurology 2017; 82 (6): 873-882. doi: 10.1002/ana.25103
41. Eshuis SA, Jager PL, Maguire RP, Jonkman S, Dierckx RA et al. Direct comparison of FP-CIT SPECT and F-DOPA PET in patients with Parkinson’s disease and healthy controls. European Journal of Nuclear Medicine and Molecular Imaging 2009; 36 (3): 454-462. doi: 10.1007/s00259-008-0989-5
42. Eshuis SA, Maguire RP, Leenders KL, Jonkman S, Jager PL. Comparison of FP-CIT SPECT with F-DOPA PET in patients with de novo and advanced Parkinson’s disease. European Journal of Nuclear Medicine and Molecular Imaging 2006; 33 (2): 200-209. doi: 10.1007/s00259-005-1904-y
43. Tinaz S, Chow C, Kuo PH, Krupinski EA, Blumenfeld H et al. Semiquantitative analysis of dopamine transporter scans in patients with Parkinson disease. Clinical Nuclear Medicine 2018; 43 (1): E1-E7. doi: 10.1097/Rlu.0000000000001885
44. Oh M, Kim JS, Kim JY, Shin KH, Park SH et al. Subregional patterns of preferential striatal dopamine transporter loss differ in Parkinson disease, progressive supranuclear palsy, and multiple-system atrophy. Journal of Nuclear Medicine 2012; 53 (3): 399-406. doi: 10.2967/jnumed.111.095224
45. Cilia R, Rossi C, Frosini D, Volterrani D, Siri C et al. Dopamine transporter SPECT imaging in corticobasal syndrome. PLoS One 2011; 6 (5): e18301. doi: 10.1371/journal.pone.0018301
46. Akdemir UO, Tokcaer AB, Karakus A, Kapucu LO. Brain 18FFDG PET imaging in the differential diagnosis of parkinsonism. Clinical Nuclear Medicine 2014; 39 (3): e220-e226. doi: 10.1097/RLU.0000000000000315
47. Brigo F, Matinella A, Erro R, Tinazzi M. [I-123]FP-CIT SPECT (DaTSCAN) may be a useful tool to differentiate between Parkinson’s disease and vascular or drug-induced parkinsonisms: a meta-analysis. European Journal of Neurology 2014; 21 (11): e89-e90. doi: 10.1111/ene.12444
48. Benitez-Rivero S, Marin-Oyaga VA, Garcia-Solis D, Huertas-Fernandez I, Garcia-Gomez FJ et al. Clinical features and 123I-FP-CIT SPECT imaging in vascular parkinsonism and Parkinson’s disease. Journal of Neurology Neurosurgery and Psychiatry 2013; 84 (2): 122-129. doi: 10.1136/jnnp-2012- 302618
49. Vizcarra JA, Lang AE, Sethi KD, Espay AJ. Vascular Parkinsonism: deconstructing a syndrome. Movement Disorders 2015; 30 (7): 886-894. doi: 10.1002/mds.26263
50. Thomas AJ, Attems J, Colloby SJ, O’Brien JT, McKeith I et al. Autopsy validation of 123I-FP-CIT dopaminergic neuroimaging for the diagnosis of DLB. Neurology 2017; 88 (3): 276-283. doi: 10.1212/WNL.0000000000003512
51. Van der Zande JJ, Booij J, Scheltens P, Raijmakers PG, Lemstra AW. [(123)]FP-CIT SPECT scans initially rated as normal became abnormal over time in patients with probable dementia with Lewy bodies. European Journal of Nuclear Medicine and Molecular Imaging 2016; 43 (6): 1060-1066. doi: 10.1007/ s00259-016-3312-x
52. Kuo PH, Lei HH, Avery R, Krupinski EA, Bauer A et al. Evaluation of an objective striatal analysis program for determining laterality in uptake of (1)(2)(3)I-ioflupane SPECT images: comparison to clinical symptoms and to visual reads. Journal of Nuclear Medicine Technology 2014; 42 (2): 105-108. doi: 10.2967/jnmt.113.134940
53. Tossici-Bolt L, Hoffmann SM, Kemp PM, Mehta RL, Fleming JS. Quantification of [123I]FP-CIT SPECT brain images: an accurate technique for measurement of the specific binding ratio. European Journal of Nuclear Medicine and Molecular Imaging 2006; 33 (12): 1491-1499. doi: 10.1007/s00259-006-0155-x
54. Calvini P, Rodriguez G, Inguglia F, Mignone A, Guerra UP et al. The basal ganglia matching tools package for striatal uptake semi-quantification: description and validation. European Journal of Nuclear Medicine and Molecular Imaging 2007; 34 (8): 1240-1253. doi: 10.1007/s00259-006-0357-2
55. Matesan M, Gaddikeri S, Longfellow K, Miyaoka R, Elojeimy S et al. I-123 DaTscan SPECT brain imaging in Parkinsonian syndromes: utility of the putamen-to-caudate ratio. Journal of Neuroimaging 2018; 28 (6): 629-634. doi: 10.1111/jon.12530
56. Nobili F, Naseri M, De Carli F, Asenbaum S, Booij J et al. Automatic semi-quantification of [123I]FP-CIT SPECT scans in healthy volunteers using BasGan version 2: results from the ENC-DAT database. European Journal of Nuclear Medicine and Molecular Imaging 2013; 40 (4): 565-573. doi: 10.1007/ s00259-012-2304-8
57. Zubal IG, Early M, Yuan O, Jennings D, Marek K et al. Optimized, automated striatal uptake analysis applied to SPECT brain scans of Parkinson’s disease patients. Journal of Nuclear Medicine 2007; 48 (6): 857-864. doi: 10.2967/ jnumed.106.037432
58. Hsu CC, Chang YH, Lin WC, Tang SW, Wang PW et al. The feasibility of using CT-guided ROI for semiquantifying striatal dopamine transporter availability in a hybrid SPECT/CT system. The Scientific World Journal 2014; 2014: 879497. doi: 10.1155/2014/879497